ChicagoA retrospective study of more than 36,000 prostate cancerbiopsies found, as expected, that the incidence of prostate cancer variedaccording to PSA levels. But the study's authors also found that the incidenceof prostate cancer was similar for men with PSAs between 2.5 and 4.0 ng/mLand those with PSAs between 4.0 and 10.0 ng/mL.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.